Viewing Study NCT00345111



Ignite Creation Date: 2024-05-05 @ 4:54 PM
Last Modification Date: 2024-10-26 @ 9:25 AM
Study NCT ID: NCT00345111
Status: WITHDRAWN
Last Update Posted: 2018-08-16
First Post: 2006-06-23

Brief Title: ACRYSOF Restor Apodized Diffractive IOL Postmarket Evaluation of Clinical Outcomes and Life-Style Visual Performance RESTOR IOL SN60WF IOL Control Group
Sponsor: University of Texas Southwestern Medical Center
Organization: University of Texas Southwestern Medical Center

Study Overview

Official Title: ACRYSOF Restor Apodized Diffractive IOL Postmarket Evaluation of Clinical Outcomes and Life-Style Visual Performance With RESTOR IOL Compared With SN60WF IOL Control Group
Status: WITHDRAWN
Status Verified Date: 2018-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Verified with former investigator that recruitment activity did not take place
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objective of the research on the Restore Intra Ocular Lens Implant IOL is to determine the clinical visual outcomes following bilateral implantation of the IOL compared to a control IOL and to demonstrate what percentage of the subjects obtain spectacle freedom
Detailed Description: The Acusof Restor IOL has recently been FDA approved This research will be an indicator by comparison to a conventional implant lens used for catract surgery The standard of care for cataract surgery is to implant an IOL to allow the patient distant vision only As a result the patient is forced to wear reading glasses or magnifying glasses for near work With the Restore IOL implant the patient will have the ability to be corrected for not only distance vision but for near and intermediate visual needs With FDA approval the statistical indications demonstate 80 of patients tested in clinical trials did not have the need for use of glasses after cataract surgery This research will further confirm and quantify the data already submitted by comparing the control group with the Restore Group in this Phase IV project

The control group of subjects will be patients who have already had cataract surgery in both eyes approximately 6 months prior to entering the study These individuals will be tested only for the 6 month evaluation in both eyes including the following tests manifest refraction which determines the best vision correction possible the near intermediate and distant visual acuity will be assessed at the respective ranges of distance contrast sensitivity will be determined by choosing the circles that have lines in them opposed to the ones that dont further assessing visual acuity stereopsis which indicates whether both eyes are functioning together pupilometry which measures the pupil diameter the life style questionaire and the life style vision evaluation form as well

The Restore IOl group of subjects post operative visual acuity data will be compared to the control subjects post operative visual data results at the distance near and intermediate ranges as well as all the other testing required at the sixxth month time frame listed above The testing will require approximately 2 hours for the 6 month visit for both control and Restore groups

The Restore group of subjects will have 4 other visits The pre operative visit will take avout 2 hours and include the following tests Manifest refraction near inermediate and distance visual acuity testing life style questionnaire and obtaining informed consent The 1 week and 1 month post-operative visit will include manifest refraction near intermediate and distance visual acuity assessment

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None